Predictive value of alkaline phosphatase for response and time to progression in bortezomib-treated multiple myeloma patients

American Journal of Hematology

Volumn 82, Issue 9, 2007, Pages 831-833

  Zangari, Maurizio ^a,f   Esseltine, Dixie ^b   Cavallo, Federica ^a   Neuwirth, Rachel ^b   Elice, Francesca ^c   Burns, Michael J ^a   Yaccoby, Shmuel ^a   Richardson, Paul ^e   Sonneveld, Pieter ^d   Tricot, Guido ^a  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^b MILLENNIUM PHARMACEUTICALS INC   (United States)

^c SAN BORTOLO HOSPITAL   (Italy)

^d ERASMUS MEDICAL CENTER   (Netherlands)

^e DANA FARBER CANCER INSTITUTE   (United States)

^f NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PHOSPHATASE; BORTEZOMIB; DEXAMETHASONE; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; BETA 2 MICROGLOBULIN; BIOLOGICAL MARKER; BORONIC ACID DERIVATIVE; PYRAZINE DERIVATIVE;

ADULT; ARTICLE; CANCER CHEMOTHERAPY; DISEASE COURSE; HUMAN; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; PREDICTION; PREDICTOR VARIABLE; PRIORITY JOURNAL; TREATMENT RESPONSE; CHI SQUARE DISTRIBUTION; CLINICAL TRIAL; COMPARATIVE STUDY; DOSE RESPONSE; FEMALE; MALE; METABOLISM; MIDDLE AGED; OSTEOBLAST; PREDICTION AND FORECASTING; STATISTICAL MODEL; TIME;

ALKALINE PHOSPHATASE; ANTINEOPLASTIC AGENTS, HORMONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BETA 2-MICROGLOBULIN; BIOLOGICAL MARKERS; BORONIC ACIDS; CHI-SQUARE DISTRIBUTION; CLINICAL TRIALS; DEXAMETHASONE; DISEASE PROGRESSION; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; OSTEOBLASTS; PREDICTIVE VALUE OF TESTS; PYRAZINES; TIME FACTORS;

EID: 35748977950     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.20961     Document Type: Article

References (11)

1. Bataille R, Chappard D, Marcelli C, et al. Recruitment of new osteoblasts and osteoclasts is the earliest critical event in the pathogenesis of human multiple myeloma. J Clin Invest 1991;88:62-66.
2. Taube T, Beneton MN, McCloskey EV, Rogers S, Greaves M, Kanis JA. Abnormal bone remodelling in patients with myelomatosis and normal biochemical indices of bone resorption. Eur J Haematol 1992;49:192-198.
3. Barille-Nion S, Bataille R. New insights in myeloma-induced osteolysis. Leuk Lymphoma 2003;44:1463-1467.
4. Roodman GD. Mechanisms of bone metastasis. N Engl J Med 2004;350:1655-1664.
5. Yaccoby S, Wezeman MJ, Zangari M, et al. Inhibitory effects of osteoblasts and increased bone formation on myeloma in novel culture systems and a myelomatous mouse model. Haematologica 2006;91:192-199.
6. Zangari M, Esseltine D, Lee CK, et al. Response to bortezomib is associated to osteoblastic activation in patients with multiple myeloma. Br J Haematol 2005;131:71-73.
7. Heider U, Kaiser M, Muller C, et al. Treatment of bortezomib increases osteoblast function in patients with multiple myeloma. Blood 2005;106:3457a.
8. Richardson PG, Sonneveld P, Schuster MW, et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 2005;352:2487-2498.
9. Bladé J, Samson D, Reece D, et al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Br J Haematol 1998;102:1115-1123.
10. Politou M, Terpos E, Anagnostopoulos A, et al. Role of receptor activator of nuclear factor-kappa B ligand (RANKL), osteoprotegerin and macrophage protein 1-alpha (MIP-1a) in monoclonal gammopathy of undetermined significance (MGUS). Br J Haematol 2004;126:686-689.
11. Richardson PG, Barlogie B, Berenson J, et al. Clinical factors predictive of outcome with bortezomib in patients with relapsed, refractory multiple myeloma. Blood 2005;106:2977-2981.